Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of SHR-9803 in advanced solid tumors
CTR20251143Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-9803 in Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Started Apr 2025; status: active.
02
Drugs
SHR-9803
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251143.